272 related articles for article (PubMed ID: 26768689)
1. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
2. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
3. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
4. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.
Fu R; Liu D; Cao Z; Zhu S; Li H; Su H; Zhang L; Xue F; Liu X; Zhang X; Cheng T; Yang R; Zhang L
Leukemia; 2016 Mar; 30(3):746-9. PubMed ID: 26118316
[No Abstract] [Full Text] [Related]
5. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
6. Capricious CALR mutated clones in myeloproliferative neoplasms.
Haslam K; Conneally E; Langabeer SE
Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
[No Abstract] [Full Text] [Related]
7. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
8. Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.
Qiao C; Sun C; Ouyang Y; Wang JJ; Qian SX; Li JY; Zhang SJ
Haematologica; 2014 Oct; 99(10):e182-4. PubMed ID: 25015940
[No Abstract] [Full Text] [Related]
9. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
ElNahass YH; Mahmoud HK; Mattar MM; Fahmy OA; Samra MA; Abdelfattah RM; ElRefaey FA; Fahmy HM; Fathy GM; Abdulgawad A; AbdelKader M; Elleithy HN; Gamil M; Talaat M; Nader HA; ElMetnawy WH
Leuk Lymphoma; 2018 Apr; 59(4):844-854. PubMed ID: 28828906
[TBL] [Abstract][Full Text] [Related]
10. Searching for CALRity in myeloproliferative neoplasms.
Cook JR
Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
[No Abstract] [Full Text] [Related]
11. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
12. Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis.
Chua CC; Omerod A; Wight J; Juneja S; Zantomio D
Pathology; 2018 Oct; 50(6):671-674. PubMed ID: 30097170
[No Abstract] [Full Text] [Related]
13. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
14. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
[TBL] [Abstract][Full Text] [Related]
16. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
18. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
19. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
20. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.
Monte-Mor Bda C; Ayres-Silva Jde P; Correia WD; Coelho AC; Solza C; Daumas AH; Bonamino MH; Santos FP; Datoguia TS; Pereira Wde O; Lisboa BC; Ramos CF; Machado-Neto JA; Hamerschlak N; Campregher PV; Traina F; Pagnano KB; Zalcberg I
Blood Cells Mol Dis; 2016 Sep; 60():74-7. PubMed ID: 26994960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
